Sugi Predict

Sugi Predict / Compounds / SCHEMBL15069186

SCHEMBL15069186

SCHEMBL15069186

Cn1cc(Br)c2cn[nH]c2c1=O

nearest known ligand 0.37

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ BRD4 O60885 8/20 0.37
▸ NOS1 P29475 2/20 0.34
▸ AXL P30530 1/20 0.34
▸ METAP2 P50579 7/20 0.33
▸ ALDH1A1 P00352 3/20 0.33
▸ HPGD P15428 2/20 0.32
▸ KDM4E B2RXH2 1/20 0.32
▸ MEN1 O00255 1/20 0.32
▸ NPC1 O15118 1/20 0.32
▸ PKM P14618 1/20 0.32
▸ ALOX12 P18054 1/20 0.32
▸ MAPK1 P28482 1/20 0.32
▸ RAB9A P51151 1/20 0.32
▸ KMT2A Q03164 1/20 0.32
▸ ATM Q13315 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22600170 0.79 BRD4 (0.40) BRD4METAP2ALDH1A1HPGDKDM4E
SCHEMBL22554197 0.77 JAK2 (0.36) BRD4METAP2ALDH1A1NPC1MAPK1
SCHEMBL22600407 0.76 HSP90AA1 (0.36) BRD4METAP2ALDH1A1HPGDKDM4E
SCHEMBL21224811 0.72 BRD4 (0.37) BRD4
SCHEMBL22554330 0.71 CYP1A2 (0.44) ALDH1A1KDM4EMEN1KMT2A
SCHEMBL15069208 0.71 BRD4 (0.58) BRD4
SCHEMBL31590048 0.70 BRD4 (0.50) BRD4METAP2
SCHEMBL17748902 0.70 CECR2 (0.45) BRD4ALDH1A1HPGDKDM4E
SCHEMBL23233752 0.69 BRD4 (0.38) BRD4
SCHEMBL31590022 0.68 BRD4 (0.43) BRD4METAP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-120040445-A Heterocyclopyridine-7-one compound and medical application thereof 浙江大学金华研究院 2025-05-27 — — CN disclosed
US-20240228489-A1 POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M1 VANDERBILT UNIVERSITY 2024-07-11 — — US disclosed
US-20240150328-A1 METHODS AND COMPOUNDS FOR TREATING DISORDERS FOGHORN THERAPEUTICS INC. 2024-05-09 — — US disclosed
US-11919902-B2 Aryl-bipyridine amine derivatives as phosphatidylinositol phosphate kinase inhibitors HIBERCELL, INC. (US) 2024-03-05 — — US disclosed
CN-112088157-B Aryl-bipyridylamine derivatives as phosphatidylinositol phosphokinase inhibitors 拉文纳制药公司 2023-12-26 — — CN disclosed
US-11773085-B2 Methods and compounds for treating disorders FOGHORN THERAPEUTICS INC. (US) 2023-10-03 — — US disclosed
US-11773085-B2 Methods and compounds for treating disorders FOGHORN THERAPEUTICS INC. (US) 2023-10-03 — — US disclosed
US-11773085-B2 Methods and compounds for treating disorders FOGHORN THERAPEUTICS INC. (US) 2023-10-03 — — US disclosed
CN-116547275-A IL-17A modulators 赛诺菲 2023-08-04 — — CN disclosed
US-20230227427-A1 IL-17A MODULATORS SANOFI (FR) 2023-07-20 — — US disclosed
WO-2015081189-A1 BICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS INCYTE CORPORATION (US) 2015-06-04 — — WO disclosed
US-20150148375-A1 BICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS INCYTE CORPORATION (US) 2015-05-28 — — US disclosed
US-20150148342-A1 BICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS INCYTE CORPORATION (US) 2015-05-28 — — US disclosed
US-20150148375-A1 BICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS INCYTE CORPORATION (US) 2015-05-28 — — US disclosed
US-20150148342-A1 BICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS INCYTE CORPORATION (US) 2015-05-28 — — US disclosed
US-20150148375-A1 BICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS INCYTE CORPORATION (US) 2015-05-28 — — US disclosed
US-20150148342-A1 BICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS INCYTE CORPORATION (US) 2015-05-28 — — US disclosed
EP-2797918-A1 BROMODOMAIN INHIBITORS AbbVie Inc. (US) 2014-11-05 — — EP disclosed
US-20140162971-A1 BROMODOMAIN INHIBITORS ABBVIE INC. 2014-06-12 — — US disclosed
WO-2013097601-A1 BROMODOMAIN INHIBITORS ABBVIE INC. (US) 2013-07-04 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150148375-A1 BICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS BRD1, BRD3, BRD2 BRD4 4/4885NOS1 4662/4885AXL 3897/4885
US-20230227427-A1 IL-17A MODULATORS IL17A, IL2, IL15 BRD4 1372/4885NOS1 858/4885AXL 3745/4885
US-20140162971-A1 BROMODOMAIN INHIBITORS BRD4, BRD1, BRD3 BRD4 1/4885NOS1 2129/4885AXL 4135/4885
US-11919902-B2 Aryl-bipyridine amine derivatives as phosphatidylinositol phosphate kinase inhibitors PIP5K1A, PIP5K1B, PIP5K1C BRD4 309/4885NOS1 3143/4885AXL 1942/4885
US-11773085-B2 Methods and compounds for treating disorders VHL, TFEB, BECN1 BRD4 57/4885NOS1 4834/4885AXL 4698/4885
US-20240150328-A1 METHODS AND COMPOUNDS FOR TREATING DISORDERS VHL, TFEB, BECN1 BRD4 57/4885NOS1 4834/4885AXL 4698/4885
US-20240228489-A1 POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M1 CHRM1, CHRM3, CHRM2 BRD4 331/4885NOS1 2108/4885AXL 2103/4885
US-20150148342-A1 BICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS BRD1, BRD3, BRD2 BRD4 4/4885NOS1 4662/4885AXL 3897/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.